Considering that the toxicity caused by GSI in humans may not be well tolerated, it is of interest whether CXCR3 inhibitor is preferable to GSI in combination with TKI against FLT3/ITD + AML for safety concerns. This evidence concerns the gene CXCR3 and acute myeloid leukemia.